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ABSTRACT
Objective: The objective of this study was to develop a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) 
method for the estimation of ledipasvir (LDP) in bulk and tablet formulation.
Methods: Stability-indicating RP-HPLC method was developed and validated for the estimation of LDP in bulk and tablet formulation. RP-HPLC was 
carried out on HiQ SiL C18 columns (250 mm × 4.6 mm, 5 μ particle size) using mobile phase acetonitrile:1 mM ammonium acetate buffer in the ratio 
of 90:10 v/v at a flow rate of 1 ml/min. The analytes were monitored using MD 2010 PDA detector at 333 nm.
Results: The retention time was found to be 3.843 min. The proposed method was found to be having linearity in the concentration range of 
5–30 µg/ml. The number of theoretical plates obtained was 4236.50 which indicate the efficient performance of the column. The limit of detection 
was 0.305 µg/ml and limit of quantification was 0.923 µg/ml, which indicate the sensitivity of the method; the high percentage recovery indicates that 
the proposed method is highly accurate. The developed method has been validated according to the ICH guidelines and found to be simple, specific, 
precise, and accurate.
Conclusion: The proposed method is precise, accurate, and stability indicating. Therefore, the proposed method can be used for routine quality 
control and analysis of LDP during stability studies in bulk samples and tablet dosage forms.
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INTRODUCTION




heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate. It is a potent 
inhibitor of HCV NS5A, a viral phosphoprotein that plays an important 
role in viral replication, assembly, and secretion. LDP in combination 
with sofosbuvir is used for the treatment of chronic hepatitis C, 
genotypes 1-6, usually in combination with other medications 
depending on the specific genotype [1,2]. A literature review revealed 
few spectrophotometric, reverse-phase high-performance liquid 
chromatography (RP-HPLC), stability-indicating RP-HPLC, and UPLC-
ESI MS/MS [3-13] methods for the estimation of LDP. The purpose of 
this work was to develop a simple basic rapid and economic stability-
indicating RP-HPLC method for the determination of LDP in its bulk and 
pharmaceutical dosage form so as to provide better scope for further 
research on the drug (Fig. 1).
METHODS
Chemical and reagents
The reagents used in this work were methanol (HPLC grade), ammonium 
acetate (AR) Grade, HCl (AR), NaOH (AR), and hydrogen peroxide (3%, 
m/v) (AR), which were procured from Merck, India. Distilled water 
(HPLC grade) was also used. LDP API was procured from Cipla.
Equipment
The instruments used in the study were HPLC (Jasco, PU 2080 Plus 
pump) integrated using Empower software, Photostability Chamber 
(Newtronic), Hot Air Oven (Kumar Laboratory Oven), electronic 
balance (Shimadzu balance), sonicator, digital pH meter, and calibrated 
glasswares.
Preparation of standard stock solution
Standard stock solution of LDP was prepared by dissolving 10 mg of 
drug in 10 ml of acetonitrile to get a concentration of 1000 µg/ml. From 
the standard stock solution, 1 ml was further diluted to 10 ml with 
mobile phase to get 100 µg/ml solution of LDP.
Analysis of formulations
Blend equivalent to 90 mg of LDP was prepared to satisfy dose/tablet 
of marketed formulation. Blend containing 90 mg LDP was prepared by 
spiking drug into excipients (20 mg starch, 4 mg magnesium stearate and 
lactose [q.s upto 200 mg]). Mixing was done by geometric addition method.
Preparation of test solutions
Blend equivalent to 10 mg of LDP was weighed and transferred to 
10 ml volumetric flask and was diluted with methanol. It was sonicated 
for 10 min and filtered so as to get solution having a concentration of 
1000 µg/ml. 1 ml of filtrate was further diluted with methanol, of which 
1 ml was diluted with mobile phase to get the final concentration of 
10 µg/ml LDP. Six determinations were carried out from homogenous 
sample to determine percentage assay.
Preparation of mobile phase
Mobile phase was prepared by mixing acetonitrile and 1 mM 
ammonium acetate buffer in the ratio of 90:10 v/v. It was then filtered 
through 0.45-µm membrane filter paper using filtration assembly and 
then sonicated on ultrasonic water bath for 10 min.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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HPLC method development
After trying several permutation and combinations, it was found that 
mixture of acetonitrile and 1 mM ammonium acetate buffer in the ratio 
of 90:10 v/v gave a sharp peak of LDP and this system was optimized. It 
was observed that the developed chromatographic condition provides 
better separation of LDP (3.843 min) as shown in Fig. 2.
Stress degradation studies of bulk drug [14]
Degradation studies of the drug substance can help to identify the likely 
degradation products which can assist to establish the degradation 
pathways and the stability of the molecule. LDP was subjected under 
different condition of acid, base, neutral hydrolysis, oxidation, dry heat, 
and photolysis. For each study, two samples were prepared (Blank and 
of LDP drug solution). The blank subjected to stress in the same manner 
as the drug solution. Dry heat and photolytic degradation were carried 
out in a solid state.
API degradation
Alkaline hydrolysis
About 1 ml working standard solution of LDP (1000 µg/ml) was 
mixed with 1 ml of 1 N methanolic NaOH and 8 ml of methanol. The 
solution was kept for 24 h in dark place. The resulting solution was 
neutralised and 2 ml was diluted with mobile phase to 10 ml and 
was injected (20 µg/ml). The chromatogram of LDP after alkaline 
hydrolysis shows 68.49% recovery, RT 3.849, and RT of degradant 
5.91 and 6.58 (Fig. 3).
Acidic hydrolysis
About 1 ml working standard solution of LDP (1000 µg/ml) was mixed 
with 1 ml of 1 N methanolic HCl and 8 ml of methanol. The solution was 
kept for 24 h in the dark place. The resulting solution was neutralised, 
and 2 ml was diluted with mobile phase to 10 ml and was injected 
(20 µg/ml). The chromatogram of LDP after acid degradation shows 
94.175% recovery, RT 3.84, and RT of degradant 6.54 (Fig. 4).
Neutral hydrolysis
About 1 ml working standard solution of LDP (1000 µg/ml) was mixed 
with 1 ml of distilled water and 8 ml of methanol. The solution was kept 
for 24 h in the dark place. 2 ml of the resulting solution was diluted with 
mobile phase to 10 ml and was injected (20 µg/ml). The chromatogram 
of LDP after neutral hydrolysis shows 87.38% recovery, RT 3.84, and RT 
of degradant 2.52 and 3.04 (Fig. 5).Fig. 1: Structure of ledipasvir
Fig. 2: Optimized chromatogram of standard ledipasvir (10 µg/ml)
Fig. 3: Chromatogram of blank NaOH and ledipasvir (20 µg/ml) after alkaline hydrolysis
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Oxidation
About 1 ml standard solution of LDP (1000 µg/ml) was mixed with 1 ml 
of 30% H2O2 solution and 8 ml of methanol. The solution was kept for 
24 h in the dark place. 2 ml of the resulting solution was diluted with 
mobile phase to 10 ml and was injected (20 µg/ml). The chromatogram 
of LDP after oxidation shows 97.07% recovery, RT 3.84, and RT of 
degradant 5.93 (Fig. 6).
Degradation under dry heat
Dry heat studies were performed by keeping drug sample in oven 
(80°C) for 24 h. Sample was withdrawn after 24 h and processed as per 
standard solution preparation procedure mentioned under 1.5 to get 
20 µg/ml as final concentration and was injected. The chromatogram 
of LDP after exposing to dry heat shows 99.781% recovery and RT 3.84 
(Fig. 7).
Fig. 4: Chromatogram of blank HCl and ledipasvir (20 µg/ml) after acid degradation
Fig. 5: Chromatogram of blank and ledipasvir (20 µg/ml) after neutral hydrolysis
Fig. 6: Chromatogram of blank H2O2 and ledipasvir (20 µg/ml) after oxidation
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Photodegradation studies
Photolytic studies were carried out by exposure of drug to UV light 
up to 200 watt-h/m2 and subsequently to cool fluorescent light to 
achieve an illumination of 1.2 million Lux.Hr. A sample was withdrawn 
after exposure and processed as per standard solution preparation 
procedure mentioned under 1.5 to get 20 µg/ml as final concentration 
and was injected. The chromatogram of LDP after photodegradation 
shows 98.71% recovery (Fig. 8).
RESULTS AND DISCUSSION
Linearity and range
From the standard stock solution (100 µg/ml) of LDP, further dilutions 
were made with mobile phase to obtain a range of solution containing 
six different concentrations. Five replicates per concentration 
were injected. The linearity (relationship between peak area and 
concentration) was determined over the concentration range of 
5–30 µg/ml as shown in Table 1.
Precision
The precision of the method was demonstrated by intra- and inter-
day variation studies. In the intraday studies, three replicates of three 
different concentrations (10, 20, and 30 µg/ml) of LDP were analyzed 
in a day, and percentage RSD was calculated. For the interday variation 
studies, three replicates of different concentrations were analyzed on 3 
consecutive days and percentage RSD was calculated as shown in Table 2.
Accuracy
To check the accuracy of the method, recovery studies were carried 
out by adding standard drug to sample at three different levels 50, 
Fig. 7: Chromatogram of ledipasvir (20 µg/ml) after exposing to dry heat
Fig. 8: Chromatogram of ledipasvir (20 µg/ml) after photodegradation
Table 1: Linearity study of LDP
Replicates Concentrations of LDP
5 µg/ml 10 µg/ml 15 µg/ml 20 µg/ml 25 µg/ml 30 µg/ml
Peak area
1 151972.1 255990.9 367001.2 469512.7 590079.1 710045.9
2 149580.2 255500.5 366714.9 470997.9 591457.7 719094.6
3 150306.9 255866.2 363674.1 471719.4 589971.6 717073.1
4 151639.5 256245.6 362299.1 488759.8 597698.1 720149.2
5 150123.1 253683.1 358676.1 483872.2 591721.1 712947.7
Mean 150724.4 255457.3 363673.1 476972.4 592185.5 715862.1
SD 1029.481 1027.496 3434.636 8739.073 3180.901 4260.782
%RSD 0.683 0.402 0.944 1.832 0.537 0.595
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100, and 150%. Basic concentration of sample chosen was 10 µg/ml 
of LDP from tablet solution. These solutions were injected in stabilized 
chromatographic conditions in triplicate to obtain the chromatograms. 
The drug concentrations of LDP were calculated using linearity 
equation of LDP as shown in Table 3.
Limit of detection (LOD)
LOD is calculated from the following formula: 
LOD = 3.3 s/S
Where,
σ = standard deviation of response for the lowest concentration in the 
range.
S = slope of the calibration curve.
Limit of quantification (LOQ)
The quantitation limit is expressed as follows:
LOQ = 10 s/S
Where,
σ = standard deviation of response for the lowest concentration in the 
range.
S = slope of the calibration curve.
Robustness
Robustness of the method was determined by carrying out the analysis 
under conditions during which flow rate and wavelengths were altered 
and the effects on the area were noted as indicated in Table 4. The 
summary of validation parameters is included in Table 5.
DISCUSSION
Stability-indicating RP-HPLC method for the determination of LDP was 
developed. Linearity for LDP was found in the range of 5–30 µg/ml with 
regression coefficient (r²) = 0.999. LOD and LOQ values were 0.30 µg/ml 
and 0.92 µg/ml, respectively. The RSD values for intra- and inter-day 
precision studies were found to be <2%.
Degradation of LDP was found to occur under acidic condition (1N HCL, 
24 h), alkaline condition (1N NaOH, 24 h), oxidative condition (30% 
H2O2, 24 h), and neutral (24 h) stress. LDP was considerably stable in 
dry heat and photostability stress testing.
CONCLUSION
In the present work, stability-indicating RP-HPLC method for the 
estimation of LDP was developed and validated as per the ICH 
guidelines. The standard deviation and % RSD (<2%) are within limit, 
indicating a high degree of precision of the methods.
From the above discussion, it can be concluded that the proposed 
method is precise, accurate, and stability indicating. Therefore, the 
proposed method can be used for routine quality control and analysis of 
LDP during stability studies in bulk samples and in tablet dosage forms.
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